

附件

# 世界反兴奋剂条例

## 国际标准

### 禁用清单

## 2025年

《禁用清单》的正式文本由世界反兴奋剂机构保存，并以英文和法文公布。如英文与法文版本、中文与英文版本存在不一致，应以英文版本为准。

本清单自2025年1月1日起生效

# TABLE OF CONTENTS

## 目 录

Please note that the list of examples of medical conditions below is not inclusive.

请注意，本目录中所列病症仅为举例。

### **SUBSTANCES & METHODS PROHIBITED AT ALL TIMES**

#### **所有场合禁用的物质和方法**

#### **S0 Non-approved substances .....6**

##### **未获批准的物质**

#### **S1 Anabolic agents .....7**

##### **蛋白同化制剂**

Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. male hypogonadism.

本类别某些物质可能存在但不限于治疗如男性性腺机能减退等疾病的药物中。

#### **S2 Peptide hormones, growth factors, related substances, and mimetics.....11**

##### **肽类激素、生长因子、相关物质和模拟物**

Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaemia, male hypogonadism, growth hormone deficiency.

本类别某些物质可能存在但不限于治疗如贫血、男性性腺机能减退、生长激素缺乏症等疾病的药物中。

#### **S3 Beta-2 agonists .....14**

##### **$\beta_2$ 激动剂**

Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. asthma and other respiratory disorders.

本类别某些物质可能存在但不限于治疗如哮喘和其他呼吸系统疾病的药物中。

#### **S4 Hormone and metabolic modulators .....16**

##### **激素及代谢调节剂**

Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. breast cancer, diabetes, infertility (female), polycystic ovarian syndrome.

本类别某些物质可能存在但不限于治疗如乳腺癌、糖尿病、不孕症(女性)、多囊卵巢综合症等疾病的药物中。

#### **S5 Diuretics and masking agents .....19**

##### **利尿剂和掩蔽剂**

Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension.

本类别某些物质可能存在但不限于治疗如心力衰竭、高血压等疾病的药物中。

<b>M1–M2–M3 Prohibited Methods.....</b>	<b>21</b>
禁用方法	

## **SUBSTANCES & METHODS PROHIBITED IN-COMPETITION**

### **赛内禁用的物质和方法**

<b>S6 Stimulants.....</b>	<b>23</b>
刺激剂	

Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaphylaxis, attention deficit hyperactivity disorders (ADHD), cold and influenza symptoms.

本类别某些物质可能存在但不限于治疗如过敏反应、注意缺陷多动障碍（ADHD）、感冒和流感症状等的药物中。

<b>S7 Narcotics .....</b>	<b>29</b>
麻醉剂	

Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. pain, including from musculoskeletal injuries.

本类别某些物质可能存在但不限于治疗如疼痛（包括肌肉骨骼损伤）的药物中。

<b>S8 Cannabinoids.....</b>	<b>30</b>
大麻（酚）类	

<b>S9 Glucocorticoids .....</b>	<b>31</b>
糖皮质激素	

Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. allergy, anaphylaxis, asthma, inflammatory bowel disease.

本类别某些物质可能存在但不限于治疗如过敏、过敏反应、哮喘、肠道炎症等疾病的药物中。

## **SUBSTANCES PROHIBITED IN PARTICULAR SPORTS**

### **特殊项目禁用物质**

<b>P1 Beta-blockers.....</b>	<b>33</b>
β-阻断剂	

Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension.

本类别某些物质可能存在但不限于治疗如心力衰竭、高血压等疾病的药物中。

附：

<b>THE 2025 MONITORING PROGRAM.....</b>	<b>35</b>
2025监控程序	

## **SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES**

<b>2025 Prohibited List.....</b>	<b>37</b>
2025年《禁用清单》主要修订及注释概要	

**THE 2025 PROHIBITED LIST**  
**2025年《禁用清单》**  
**WORLD ANTI-DOPING CODE**  
**《世界反兴奋剂条例》**  
VALID 1 JANUARY 2025  
2025年1月1日起生效

**Introduction**

**引言**

The *Prohibited List* is a mandatory *International Standard* as part of the World Anti-Doping Program.

《禁用清单》是强制性的国际标准，是世界反兴奋剂体系的组成部分。

The *List* is updated annually following an extensive consultation process facilitated by WADA. The effective date of the *List* is 01 January 2025.

《禁用清单》由世界反兴奋剂机构（以下简称“WADA”）在广泛征求意见后发布，每年更新一次。本《禁用清单》自2025年1月1日起生效。

The official text of the *Prohibited List* shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.

《禁用清单》的正式文本应由WADA保存，并以英文和法文版本公布。如英文与法文版本存在不一致，应以英文版本为准。

Below are some terms used in this *List of Prohibited Substances and Prohibited Methods*.

以下是本《禁用物质和方法清单》中使用的一些术语。

***Prohibited In-Competition***

**赛内禁用**

Subject to a different period having been approved by WADA for a given sport, the *In-Competition* period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a *Competition* in which the *Athlete* is scheduled to participate until the end of the *Competition* and the *Sample* collection process.

赛内原则上是指从运动员计划参赛的前一天晚11:59开始，直至该比赛和与之相关样本采集程序结束为止的一段时间，除非WADA为某一特定运动项目批准了不同的时间段。

***Prohibited at all times***

**所有场合禁用**

This means that the substance or method is prohibited *In-* and *Out-of-Competition* as defined in the *Code*.

即该物质或方法在《条例》定义的赛内和赛外均禁用。

***Specified and non-Specified***

## 特定和非特定

As per Article 4.2.2 of the *World Anti-Doping Code*, “for purposes of the application of Article 10, all *Prohibited Substances* shall be *Specified Substances* except as identified on the *Prohibited List*. No *Prohibited Method* shall be a *Specified Method* unless it is specifically identified as a *Specified Method* on the *Prohibited List*”. As per the comment to the article, “the *Specified Substances* and *Methods* identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an *Athlete* for a purpose other than the enhancement of sport performance.”

依照《条例》条款4.2.2, “为适用第10条, 除《禁用清单》中明确列出以外, 所有禁用物质均为特定物质。除非在《禁用清单》上明确规定为特定方法, 否则任何禁用方法均不属于特定方法”。根据该条款释义, “条款4.2.2中确定的特定物质和特定方法不应当视为没有其他兴奋剂物质或方法重要或危险。相反, 这些物质和方法更容易被运动员服用或使用, 用于提高运动能力以外的其他目的。”

## *Substances of Abuse*

### 滥用物质

Pursuant to Article 4.2.3 of the Code, *Substances of Abuse* are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated *Substances of Abuse*: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/“ecstasy”), tetrahydrocannabinol (THC)

依照《条例》条款4.2.3, 滥用物质是指经常在体育运动以外的社会环境中被滥用的物质。下列物质被指定为滥用物质: 可卡因, 二醋吗啡(海洛因), *N*-甲基亚甲二氧基苯丙胺[MDMA/亚甲基二氧甲基苯丙胺(中文注: 摇头丸主要成分)], 四氢大麻酚(THC)。

## **S0. NON-APPROVED SUBSTANCES**

### **未获批准的物质**

#### **PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)**

**所有场合禁用（赛内和赛外）**

All prohibited substances in this class are *Specified Substances*.

本类别中所有禁用物质均为特定物质。

Any pharmacological substance which is not addressed by any of the subsequent sections of the *List* and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

本《禁用清单》以下各节未涉及且目前尚未获得任何政府健康管理部门批准用于人体治疗的任何药理学物质（例如：处于临床前或临床开发中或已终止临床试验的药物、设计药物、仅批准用于兽医的物质），在所有场合都禁用。

This class covers many different substances including but not limited to BPC-157, 2,4-dinitrophenol (DNP), ryanodine receptor-1-calstabin complex stabilizers [e.g. S-107, S48168 (ARM210)] and troponin activators (e.g. reldesemtiv and tirasemtiv).

本类别涵盖许多不同的物质，包括但不限于BPC-157, 2,4-二硝基苯酚(DNP), 兰尼碱受体-1-钙稳定蛋白复合物稳定剂（阿诺碱受体-1-钙稳定蛋白复合物稳定剂）（例如：S-107和S48168（ARM210））和肌钙蛋白激活剂（例如：瑞地生替和泰拉生替）。

# S1. ANABOLIC AGENTS

## 蛋白同化制剂

### PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

所有场合禁用（赛内和赛外）

All prohibited substances in this class are non-*Specified Substances*.

本类别中所有禁用物质均为非特定物质。

Anabolic agents are prohibited.

蛋白同化制剂禁用。

### S1.1. ANABOLIC ANDROGENIC STEROIDS(AAS)

#### 蛋白同化雄性类固醇（AAS）

When administered exogenously, including but not limited to:

外源性摄入时禁用，包括但不限于：

- 1-Androstenediol( $5\alpha$ -androst-1-ene- $3\beta$ , $17\beta$ -diol)  
1-雄烯二醇（ $5\alpha$ -雄甾-1-烯- $3\beta$ ， $17\beta$ -二醇）
- 1-Androstenedione( $5\alpha$ -androst-1-ene-3, $17$ -dione)  
1-雄烯二酮（ $5\alpha$ -雄甾-1-烯-3， $17$ -二酮）
- 1-Androsterone( $3\alpha$ -hydroxy- $5\alpha$ -androst-1-ene- $17$ -one)  
1-雄酮（ $3\alpha$ -羟基- $5\alpha$ -雄甾-1-烯- $17$ -酮）
- 1-Epiandrosterone( $3\beta$ -hydroxy- $5\alpha$ -androst-1-ene- $17$ -one)  
1-表雄酮（ $3\beta$ -羟基- $5\alpha$ -雄甾-1-烯- $17$ -酮）
- 1-Testosterone( $17\beta$ -hydroxy- $5\alpha$ -androst-1-en-3-one)  
1-睾酮（ $17\beta$ -羟基- $5\alpha$ -雄甾-1-烯-3-酮）
- 4-Androstenediol( $androst$ -4-ene- $3\beta$ , $17\beta$ -diol)  
4-雄烯二醇（雄甾-4-烯- $3\beta$ ， $17\beta$ -二醇）
- 4-Hydroxytestosterone( $4,17\beta$ -dihydroxyandrost-4-en-3-one)  
4-羟基睾酮（4， $17\beta$ -二羟基雄甾-4-烯-3-酮）
- 5-Androstenedione( $androst$ -5-ene-3, $17$ -dione)  
5-雄烯二酮（雄甾-5-烯-3， $17$ -二酮）
- $7\alpha$ -Hydroxy-DHEA  
 $7\alpha$ -羟基-普拉睾酮
- $7\beta$ -Hydroxy-DHEA  
 $7\beta$ -羟基-普拉睾酮
- 7-Keto-DHEA  
7-羰基-普拉睾酮
- $11\beta$ -Methyl-19-nortestosterone  
 $11\beta$ -甲基-19-去甲睾酮
- $17\alpha$ -Methylepithiostanol(epistane)  
甲基环硫雄醇

- 19-Norandrostenediol(estr-4-ene-3,17-diol)  
19-去甲雄烯二醇（雌甾-4-烯-3, 17-二醇）
- 19-Norandrostenedione(estr-4-ene-3,17-dione)  
19-去甲雄烯二酮（雌甾-4-烯-3, 17-二酮）
- Androst-4-ene-3,11,17- trione (11-ketoandrostenedione, adrenosterone)  
雄甾-4-烯-3, 11, 17-三酮（11-羰基-4-雄烯二酮，肾上腺雄甾酮）
- Androstanolone (5 $\alpha$ -dihydrotestosterone,17 $\beta$ -hydroxy-5 $\alpha$ -androstan-3-one)  
雄诺龙（5 $\alpha$ -双氢睾酮，17 $\beta$ -羟基-5 $\alpha$ -雄烷-3-酮）
- Androstenediol (androst-5-ene-3 $\beta$ ,17 $\beta$ -diol)  
5-雄烯二醇（雄甾-5-烯-3 $\beta$ , 17 $\beta$ -二醇）
- Androstenedione(androst-4-ene-3,17-dione)  
4-雄烯二酮（雄甾-4-烯-3, 17-二酮）
- Bolasterone  
勃拉睾酮
- Boldenone  
勃地酮
- Boldione (androsta-1,4-diene-3,17-dione)  
1,4-雄烯二酮（雄甾-1, 4-二烯-3, 17-二酮）
- Calusterone  
卡芦睾酮
- Clostebol  
氯司替勃
- Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17 $\alpha$ -ol)  
达那唑（[1, 2]噁唑[4', 5':2, 3]孕甾-4-烯-20-炔-17 $\alpha$ -醇）
- Dehydrochlormethyltestosterone  
(4-chloro-17 $\beta$ -hydroxy-17 $\alpha$ -methylandrosta-1,4-dien-3-one)  
去氢氯甲睾酮（脱氢氯甲睾酮，4-氯-17 $\beta$ -羟基-17 $\alpha$ -甲基雄甾-1, 4-二烯-3-酮）
- Desoxymethyltestosterone (17 $\alpha$ -methyl-5 $\alpha$ -androst-2-en-17 $\beta$ -ol and  
17 $\alpha$ -methyl-5 $\alpha$ -androst-3-en-17 $\beta$ -ol)  
去氧甲睾酮（17 $\alpha$ -甲基-5 $\alpha$ -雄甾-2-烯-17 $\beta$ -醇 和 17 $\alpha$ -甲基-5 $\alpha$ -雄甾-3-烯-17 $\beta$ -醇）
- Dimethandrolone (7 $\alpha$ ,11 $\beta$ -Dimethyl-19-nortestosterone)  
二甲基诺龙（7 $\alpha$ , 11 $\beta$ -二甲基-19-去甲睾酮）
- Drostanolone  
屈他雄酮
- Epiandrosterone(3 $\beta$ -hydroxy-5 $\alpha$ -androstan-17-one)  
表雄酮（3 $\beta$ -羟基-5 $\alpha$ -雄烷-17-酮）
- Epi-dihydrotestosterone(17 $\beta$ -hydroxy-5 $\beta$ -androstan-3-one)  
表双氢睾酮（17 $\beta$ -羟基-5 $\beta$ -雄烷-3-酮）
- Epitestosterone  
表睾酮
- Ethylestrenol(19-norpregna-4-en-17 $\alpha$ -ol)  
乙雌烯醇（19-去甲孕-4-烯-17 $\alpha$ -醇）
- Fluoxymesterone  
氟甲睾酮



- Formebolone  
甲酰勃龙
- Furazabol(17 $\alpha$ -methyl[1,2,5]oxadiazolo[3',4':2,3]-5 $\alpha$ -androstan-17 $\beta$ -ol)  
夫拉扎勃 (17 $\alpha$ -甲基[1,2,5]噁二唑[3',4':2,3]-5 $\alpha$ -雄烷-17 $\beta$ -醇)
- Gestrinone  
孕三烯酮
- Mestanolone  
美雄诺龙
- Mesterolone  
美睾酮
- Metandienone (17 $\beta$ -hydroxy-17 $\alpha$ -methylandrosta-1,4-dien-3-one)  
美雄酮 (17 $\beta$ -羟基-17 $\alpha$ -甲基雄甾-1,4-二烯-3-酮)
- Metenolone  
美替诺龙
- Methandriol  
美雄醇
- Methasterone (17 $\beta$ -hydroxy-2 $\alpha$ ,17 $\alpha$ -dimethyl-5 $\alpha$ -androstan-3-one)  
甲基屈他雄酮 (17 $\beta$ -羟基-2 $\alpha$ ,17 $\alpha$ -二甲基-5 $\alpha$ -雄烷-3-酮)
- Methyl-1-testosterone (17 $\beta$ -hydroxy-17 $\alpha$ -methyl-5 $\alpha$ -androst-1-en-3-one)  
甲基-1-睾酮 (17 $\beta$ -羟基-17 $\alpha$ -甲基-5 $\alpha$ -雄甾-1-烯-3-酮)
- Methylclostebol  
甲基氯司替勃
- Methyldienolone (17 $\beta$ -hydroxy-17 $\alpha$ -methylestra-4,9-dien-3-one)  
甲二烯诺龙 (17 $\beta$ -羟基-17 $\alpha$ -甲基雌甾-4,9-二烯-3-酮)
- Methylnortestosterone(17 $\beta$ -hydroxy-17 $\alpha$ -methylestr-4-en-3-one)  
甲诺睾酮 (17 $\beta$ -羟基-17 $\alpha$ -甲基雌甾-4-烯-3-酮)
- Methyltestosterone  
甲睾酮
- Metribolone (methyltrienolone,17 $\beta$ -hydroxy-17 $\alpha$ -methylestra-4,9,11-trien-3-one)  
美曲勃龙 (甲基群勃龙,17 $\beta$ -羟基-17 $\alpha$ -甲基雌甾-4,9,11-三烯-3-酮)
- Mibolerone  
米勃酮
- Nandrolone (19-nortestosterone)  
诺龙 (19-去甲睾酮)
- Norboletone  
诺勃酮
- Norclostebol (4-chloro-17 $\beta$ -ol-estr-4-en-3-one)  
诺司替勃 (4-氯-17 $\beta$ -醇-雌甾-4-烯-3-酮)
- Norethandrolone  
诺乙雄龙
- Oxabolone  
羟勃龙
- Oxandrolone  
氧雄龙

- Oxymesterone  
羟甲睾酮
- Oxymetholone  
羟甲烯龙
- Prasterone (dehydroepiandrosterone, DHEA, 3 $\beta$ -hydroxyandrost-5-en-17-one)  
普拉睾酮 (脱氢表雄酮, 3 $\beta$ -羟基雄甾-5-烯-17-酮)
- Prostanozol (17 $\beta$ -[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5 $\alpha$ -androstane)  
前列他唑 (17 $\beta$ -[(四氢吡喃-2-基)氧]-1'氢-吡唑[3,4:2,3]-5 $\alpha$ -雄烷)
- Quinbolone  
奎勃龙
- Stanozolol  
司坦唑醇
- Stenbolone  
司腾勃龙
- Testosterone  
睾酮
- Tetrahydrogestrinone (17-hydroxy-18 $\alpha$ -homo-19-nor-17 $\alpha$ -pregna-4,9,11-trien-3-one)  
四氢孕三烯酮 (17-羟基-18 $\alpha$ -增-19-去甲基-17 $\alpha$ -孕甾-4,9,11-三烯-3-酮)
- Tibolone  
替勃龙
- Trenbolone (17 $\beta$ -hydroxyestr-4,9,11-trien-3-one)  
群勃龙 (17 $\beta$ -羟基雌甾-4,9,11-三烯-3-酮)
- Trestolone (7 $\alpha$ -Methyl-19-nortestosterone, MENT)  
曲托龙 (7 $\alpha$ -甲基-19-去甲睾酮, MENT)

and other substances with a similar chemical structure or similar biological effect(s).  
以及其他具有类似化学结构或类似生物效应的物质。

## **S1.2. OTHER ANABOLIC AGENTS**

### **其他蛋白同化制剂**

Including, but not limited to:

包括但不限于:

Clenbuterol, osilodrostat, ractopamine, selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033(ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol.

克仑特罗, 奥唑司他, 雷托巴胺(莱克多巴胺), 选择性雄激素受体调节剂[SARMs, 例如: andarine, 依诺波沙 (ostarine), LGD-4033 (ligandrol), RAD140, S-23 和YK-11], 泽仑诺和齐帕特罗。

## **S2. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS**

### **肽类激素、生长因子、相关物质和模拟物**

#### **PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)**

所有场合禁用（赛内和赛外）

All prohibited substances in this class are non-*Specified Substances*.

本类别中所有禁用物质均为非特定物质。

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited.

下列物质以及其他具有类似化学结构或类似生物效应的物质，均禁用。

#### **S2.1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS**

促红素类以及影响红细胞生成的制剂

Including, but not limited to:

包括但不限于：

S2.1.1 Erythropoietin receptor agonists, e.g. darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide)

促红素受体激动剂类，例如：达促红素（dEPO）；促红素类（EPO）；基于促红素类分子结构的构建物[例如：EPO-Fc融合蛋白（EPO-Fc融合蛋白），培促红素β（CERA）]；促红素模拟物及其构建物[例如：EPO-Fc（IgG4）融合蛋白（CNTO-530），培尼沙肽]。

S2.1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon.

缺氧诱导因子(HIF)激活剂类，例如：钴化合物；达普司他(GSK1278863)；特异性的脯氨酰羟化酶-2（PHD2）抑制剂（IOX2）；莫立司他（BAY 85-3934）；罗沙司他（FG-4592）；伐达度司他（AKB-6548）；氙气。

S2.1.3 GATA inhibitors, e.g. K-11706.

GATA抑制剂，例如：K-11706。

S2.1.4 Transforming growth factor beta (TGF-β) signalling inhibitors, e.g. luspatercept; sotatercept.

转化生长因子-β（TGF-β）抑制剂，例如：罗特西普；索特西普。

S2.1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO).

先天修复受体激动剂类，例如：唾液酸促红素；氨甲酰促红素（CEPO）。

## S2.2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS

### 肽类激素及其释放因子

S2.2.1 Testosterone-stimulating peptides in males including, but not limited to:

- chorionic gonadotrophin (CG),
- luteinizing hormone (LH),
- gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues (e.g. buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin),
- kisspeptin and its agonist analogues  
辜酮刺激肽（男性禁用），包括但不限于：
  - 绒毛膜促性腺激素（CG），
  - 促黄体生成素（LH），
  - 促性腺激素释放激素（GnRH，戈那瑞林）及其激动剂类似物（例如：布舍瑞林、地洛瑞林、戈舍瑞林、组氨瑞林、亮丙瑞林、那法瑞林和曲普瑞林），
  - kisspeptin及其激动剂类似物。

S2.2.2 Corticotrophins and their releasing factors, e.g. corticorelin and tetracosactide

促皮质素类及其释放因子，例如：可的瑞林和替可克肽。

S2.2.3 Growth hormone (GH), its analogues and fragments including, but not limited to:

生长激素（GH）及其类似物和片段，包括但不限于：

- growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogen  
生长激素类似物，例如：隆培促生长素，帕西生长素和曲更生长素。
- growth hormone fragments, e.g. AOD-9604 and hGH 176-191  
生长激素片段，例如：AOD-9604和人生长激素176-191(hGH 176-191)。

S2.2.4 Growth hormone releasing factors, including, but not limited to:

生长激素释放因子，包括但不限于：

- growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin);
- 生长激素释放激素（GHRH）及其类似物（例如：合成的生长激素释放肽（CJC-1293, CJC-1295），舍莫瑞林和替莫瑞林）。
- growth hormone secretagogues (GHS) and their mimetics [e.g. anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin];
- 生长激素促分泌剂类（GHS）及其模拟物 [例如：阿那瑞林，卡莫瑞林，伊布莫仑(MK-677)，伊莫瑞林，来诺瑞林（葛瑞林（脑肠肽）），马昔瑞林和他莫瑞林]。
- GH-releasing peptides (GHRPs) [e.g. alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6];

- 生长激素释放肽类（GHRPs），[例如：艾瑞莫瑞林，艾莫瑞林（海沙瑞林），生长激素释放肽-1（GHRP-1），生长激素释放肽-2（普拉莫瑞林），生长激素释放肽-3（GHRP-3），生长激素释放肽-4（GHRP-4），生长激素释放肽-5（GHRP-5）和生长激素释放肽-6（GHRP-6）]。

### **S2.3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS**

#### **生长因子以及生长因子调节剂**

Including, but not limited to:

包括但不限于：

- Fibroblast Growth Factors (FGFs)

成纤维细胞生长因子类（FGFs）

- Hepatocyte Growth Factor (HGF)

肝细胞生长因子（HGF）

- Insulin-like Growth Factor-1(IGF-1, mecaseprin) and its analogues

胰岛素样生长因子1（IGF-1，美卡舍明）及其类似物

- Mechano Growth Factors (MGFs)

机械生长因子类（MGFs）

- Platelet-Derived Growth Factor (PDGF)

血小板衍生生长因子（PDGF）

- Thymosin-β4 and its derivatives e.g. TB-500

胸腺肽-β4及其衍生物，例如：TB-500

- Vascular endothelial Growth Factor (VEGF)

血管内皮生长因子（VEGF）

and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

以及其他影响肌肉、肌腱或韧带蛋白质合成/分解、血管形成、能量利用、再生能力或纤维类型转换的生长因子或生长因子调节剂。

### S3. BETA-2 AGONISTS

#### β<sub>2</sub>激动剂

##### PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

所有场合禁用（赛内和赛外）

All prohibited substances in this class are *Specified Substances*.

本类别中所有禁用物质均为特定物质。

All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited.

所有选择性和非选择性β<sub>2</sub>激动剂，包括所有光学异构体，均禁用。

Including, but not limited to:

包括但不限于：

•Arformoterol

阿福特罗

•Fenoterol

非诺特罗

•Formoterol

福莫特罗

•Higenamine

去甲乌药碱

•Indacaterol

茚达特罗

•Levosalmeterol

左沙丁胺醇

•Olodaterol

奥达特罗

•Procaterol

丙卡特罗

•Reproterol

瑞普特罗

•Salbutamol

沙丁胺醇

•Salmeterol

沙美特罗

•Terbutaline

特布他林

•Tretinoin (tretinoin)

曲托喹酚（tretinoin）

•Tulobuterol

妥洛特罗

- Vilanterol  
维兰特罗

## EXCEPTIONS

### 例外

- Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 600 micrograms over 8 hours starting from any dose;  
吸入使用沙丁胺醇 (salbutamol) : 24小时内最多不超过1600微克, 任意8小时不超过600微克;
- Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours in divided doses not to exceed 36 micrograms over 12 hours starting from any dose;  
吸入使用福莫特罗 (formoterol) : 24小时内最多不超过54微克, 任意12小时不超过36微克;
- Inhaled salmeterol: maximum 200 micrograms over 24 hours;  
吸入使用沙美特罗 (salmeterol) : 24小时内最多不超过200微克;
- Inhaled vilanterol: maximum 25 micrograms over 24 hours.  
吸入使用维兰特罗 (vilanterol) : 24小时内最多不超过25微克。

## NOTE

### 注意

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an *Adverse Analytical Finding (AAF)* unless the *Athlete* proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above.

若尿液中沙丁胺醇浓度超过1000ng/ml, 或福莫特罗浓度超过40ng/ml, 不符合该物质的治疗用途, 将被视为阳性检测结果 (AAF)。除非运动员通过受控的药代动力学研究, 证明该异常结果是由于治疗性吸入上述最大剂量药物所致。

## S4. HORMONE AND METABOLIC MODULATORS

### 激素及代谢调节剂

#### PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

所有场合禁用（赛内和赛外）

Prohibited substances in classes S4.1 and S4.2 are *Specified Substances*. Those in classes S4.3 and S4.4 are non-*Specified Substances*.

S4.1和S4.2中的禁用物质为特定物质。S4.3和S4.4中的禁用物质为非特定物质。

The following hormone and metabolic modulators are prohibited:

下列激素和代谢调节剂禁用：

#### S4.1. AROMATASE INHIBITORS

##### 芳香酶抑制剂

Including, but not limited to:

包括但不限于：

- 2-Androst-enol(5 $\alpha$ -androst-2-en-17-ol)  
2-雄烯醇（5 $\alpha$ -雄甾-2-烯-17-醇）
- 2-Androst-enone(5 $\alpha$ -androst-2-en-17-one)  
2-雄酮（5 $\alpha$ -雄甾-2-烯-17-酮）
- 3-Androst-enol(5 $\alpha$ -androst-3-en-17-ol)  
3-雄烯醇（5 $\alpha$ -雄甾-3-烯-17-醇）
- 3-Androst-enone (5 $\alpha$ -androst-3-en-17-one)  
3-雄酮（5 $\alpha$ -雄甾-3-烯-17-酮）
- 4-Androstene-3,6,17-trione(6-oxo)  
4-雄烯-3,6,17-三酮（6-氧代）
- Aminoglutethimide  
氨鲁米特
- Anastrozole  
阿那罗唑
- Androsta-1,4,6-triene-3,17-dione(androstatrienedione)  
雄甾-1,4,6-三烯-3,17-二酮（雄三烯二酮）
- Androsta-3,5-diene-7,17-dione(arimistane)  
雄甾-3,5-二烯-7,17-二酮（arimistane）
- Exemestane  
依西美坦
- Formestane  
福美坦
- Letrozole  
来罗唑
- Testolactone



甾内酯

#### **S4.2. ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS(SERMS)]**

抗雌激素作用物质[抗雌激素和选择性雌激素受体调节剂 (SERMS) ]

Including, but not limited to:

包括但不限于:

- Bazedoxifene  
巴多昔芬
- Clomifene  
氯米芬
- Cyclofenil  
环芬尼
- Elacestrant  
艾拉司群
- Fulvestrant  
氟维司群
- Ospemifene  
奥培米芬
- Raloxifene  
雷洛昔芬
- Tamoxifen  
他莫昔芬
- Toremifene  
托瑞米芬

#### **S4.3. AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION**

激活素受体IIB活化抑制剂类

Including, but not limited to:

包括但不限于:

- Activin A-neutralizing antibodies  
激活素A中和抗体类
- Activin receptor IIB competitors such as:  
激活素受体IIB竞争剂类, 例如:
  - Decoy activin receptors (e.g.ACE-031)  
伪激活素受体类 (例如: ACE-031)
- Anti-activin receptor IIB antibodies (e.g. Bimagrumab)  
激活素受体IIB抗体类 (例如: 比马鲁单抗)
- Myostatin inhibitors such as:  
肌抑素抑制剂类, 例如:
  - Agents reducing or ablating myostatin expression  
肌抑素表达消减剂类
  - Myostatin-binding proteins (e.g. Follistatin, myostatin propeptide)

- 肌抑素结合蛋白类（例如：卵泡抑素，肌抑素前肽）
- Myostatin- or precursor-neutralizing antibodies (e.g. apitegromab, domagrozumab, landogrozumab, stamulumab)
- 肌抑素或其前体的中和抗体类（例如：阿匹特古单抗，多古珠单抗，兰度古珠单抗，司他利尤单抗）

#### **S4.4. METABOLIC MODULATORS:**

##### 代谢调节剂:

##### S4.4.1

- Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR; mitochondrial open reading frame of the 12S rRNA-c (MOTS-c);

腺苷酸活化蛋白激酶（AMPK）激动剂，例如：阿卡地新（AICAR）；基于12S rRNA-C的线粒体开放阅读框（MOTS-c）；

- Peroxisome proliferator-activated receptor delta (PPAR $\delta$ ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516) and;

过氧化物酶体增植物激活受体 $\delta$ （PPAR $\delta$ ）激动剂，例如：2-(2-甲基-4-((4-甲基-2-(4-(三氟甲基)苯基)噻唑-5-基)甲硫基)苯氧基)乙酸(GW1516, GW501516)和；

- Rev-erba agonists, e.g. SR9009, SR9011;

Rev-Erba激动剂，例如：SR9009, SR9011；

##### S4.4.2 Insulins and insulin-mimetics, e.g. S519, S597

胰岛素类以及胰岛素模拟物类，例如：S519, S597

##### S4.4.3 Meldonium;

美度铵

##### S4.4.4 Trimetazidine;

曲美他嗪

## S5. DIURETICS AND MASKING AGENTS

### 利尿剂和掩蔽剂

#### PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

所有场合禁用(赛内和赛外)

All prohibited substances in this class are *Specified Substances*.

本类别中所有禁用物质均为特定物质。

All diuretics and masking agents, including all optical isomers, e.g. *d*- and *l*- where relevant, are prohibited.

下列利尿剂和掩蔽剂，包括所有光学异构体，例如*d*-型和*l*-型，均禁用。

Including, but not limited to:

包括但不限于：

- Diuretics such as:

Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene; xipamide;

利尿剂，例如：乙酰唑胺；阿米洛利；布美他尼；坎利酮；氯噻酮；依他尼酸；呋塞米；吲达帕胺；美托拉宗；螺内酯；噻嗪类，例如：卞氟噻嗪、氯噻嗪和氢氯噻嗪；托拉塞米；氨苯蝶啶；希帕胺；

- Vaptans, e.g. conivaptan, mozavaptan, tolvaptan;

伐坦类，例如：考尼伐坦，莫扎伐坦（莫扎伐普坦），托伐普坦

- Plasma expanders by intravenous administration such as: albumin, dextran, hydroxyethyl starch and mannitol.

静脉输入血容量扩充剂类，例如：白蛋白、右旋糖酐、羟乙基淀粉和甘露醇。

- Desmopressin;

去氨加压素

- Probenecid;

丙磺舒

and other substances with a similar chemical structure or similar biological effect(s).

以及其他具有类似化学结构或者类似生物效应的物质。

#### EXCEPTIONS

##### 例外

- Drospirenone; pamabrom; and topical ophthalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide);

屈螺酮、巴马溴以及眼科局部用药的碳酸酐酶抑制剂（例如：多佐胺，布林佐胺）

- Local administration of felypressin in dental anaesthesia.

牙科局部麻醉中使用的苯赖加压素。

## NOTE

### 注意

The detection in an *Athlete's Sample* at all times or *In-Competition*, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, (except topical ophthalmic administration of a carbonic anhydrase inhibitor or local administration of felypressin in dental anaesthesia), will be considered as an *Adverse Analytical Finding(AAF)* unless the *Athlete* has an approved *Therapeutic Use Exemption(TUE)* for that substance in addition to the one granted for the diuretic or masking agent.

如在运动员任何场合或赛内检查的样本中（视情况而定）检测出利尿剂或掩蔽剂（除了碳酸酐酶抑制剂的眼部局部给药，或苯赖加压素在牙科麻醉中的局部给药）的同时，检出任意浓度的以下阈值物质：福莫特罗、沙丁胺醇、去甲伪麻黄碱、麻黄碱、甲基麻黄碱和伪麻黄碱，将视为阳性检测结果（AAF），除非运动员已经获得该阈值物质以及利尿剂或掩蔽剂的治疗用药豁免（TUE）批准。

## PROHIBITED METHODS

### 禁用方法

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

所有场合禁用（赛内和赛外）

All prohibited methods in this class are non-*Specified* except methods in M2.2. which are *Specified Methods*.

除M2.2.中的禁用方法为特定方法外，本类别中所有禁用方法均为非特定方法。

### M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS

#### 篡改血液和血液成分

The following are prohibited:

以下方法禁用：

M1.1. The *Administration* or reintroduction of any quantity of autologous, allogenic(homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.

向循环系统中注入或回输任何来源及任何数量的自体、同种异体（同源）或异源血液或红细胞制品。

#### NOTE

#### 注意

Donation of blood or blood components, including by apheresis, is not prohibited when performed in a collection center accredited by the relevant regulatory authority of the country in which it operates

在经所在国相关监管机构认可的采集中心进行的血液或血液成分捐献，包括通过单采术采集，不予禁止。

M1.2. Artificially enhancing the uptake, transport or delivery of oxygen.

人为提高氧气摄入、输送或释放的方法。

Including, but not limited to:

Perfluorochemicals; efaproxiral (RSR13); voxelotor and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation.

包括但不限于：

使用全氟化合物、乙丙昔罗（RSR13）、伏塞洛托及经修饰的血红蛋白制剂（如以血红蛋白为主剂的血液替代品，微囊血红蛋白制剂等）。以吸入的方法补充氧气不禁用。

M1.3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

通过物理或化学手段，以任何形式向血管内输送全血或血液成分。

### M2. CHEMICAL AND PHYSICAL MANIPULATION

### 化学和物理篡改

The following are prohibited:

以下方法禁用：

M2.1. *Tampering, or Attempting to Tamper*, to alter the integrity and validity of *Samples* collected during *Doping Control*.

在兴奋剂检查过程中，禁止篡改或企图篡改样本的完整性和有效性的行为。

Including, but not limited to:

*Sample* substitution and/or adulteration, e.g. addition of proteases to *Sample*.

包括但不限于：

置换样品和/或变更样品，例如，向样品中添加蛋白酶。

M2.2. Intravenous infusions and/or injections of more than a total of 100mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.

每12小时的静脉输液和/或静脉注射量累计超过100ml，但在医院治疗、手术治疗或临床诊断检查过程中正当的使用除外。

### M3. GENE AND CELL DOPING

#### 基因和细胞兴奋剂

The following, with the potential to enhance sport performance, are prohibited:

以下具有潜在提高运动能力的手段禁用：

M3.1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies.

使用核酸或核酸类似物，可以改变基因组序列和/或通过任何机制改变基因表达。这包括但不限于基因编辑、基因沉默和基因转移技术。

M3.2. The use of normal or genetically modified cells.

使用常规或经基因修饰的细胞。

## S6. STIMULANTS

### 刺激剂

#### PROHIBITED IN-COMPETITION

##### 赛内禁用

All prohibited substances in this class are *Specified Substances* except those in S6.A, which are non-*Specified Substances*.

除S6.A中的禁用物质为非特定物质外，本类别中的所有其他禁用物质均为特定物质。

*Substances of Abuse* in this section: cocaine and methylenedioxymethamphetamine (MDMA/“ecstasy”)

本节内的滥用物质：可卡因和N-甲基亚甲二氧基苯丙胺 [MDMA/“亚甲基二氧甲基苯丙胺”(中文注：摇头丸主要成分)]。

All stimulants, including all optical isomers, e.g. *d*- and *l*-where relevant, are prohibited.

所有刺激剂，包括所有光学异构体（例如*d*-型和*l*-型）均禁用。

Stimulants include:

刺激剂包括：

#### S6.A: NON-SPECIFIED STIMULANTS

非特定刺激剂：

•Adrafinil

阿屈非尼

•Amfepramone

安非拉酮

•Amfetamine

苯丙胺

•Amfetaminil

安非他尼

•Amiphenazole

阿米苯唑

•Benfluorex

苯氟雷司

•Benzylpiperazine

苄基哌嗪

•Bromantan

布罗曼坦

•Clobenzorex

氯苄雷司

•Cocaine

可卡因  
•Cropropamide  
克罗丙胺  
•Crotetamide  
克罗乙胺  
•Fencamine  
芬咖明  
•Fenetylline  
芬乙茶碱  
•Fenfluramine  
芬氟拉明  
•Fenproporex  
芬普雷司  
•Fonturacetam[4-phenylpiracetam(carphedon)]  
芳妥西坦[4-苯基吡拉西坦（卡非多）]  
•Furfenorex  
呋芬雷司  
•Hydrafinil (fluorenol)  
羟基苄（苄醇）  
•Lisdexamfetamine  
利右苯丙胺  
•Mefenorex  
美芬雷司  
•Mephentermine  
美芬丁胺  
•Mesocarb  
美索卡  
•Metamfetamine(*d*-)  
甲基苯丙胺（右旋）  
•*p*-methyldamphetamine  
对-甲基苯丙胺  
•Modafinil  
莫达非尼  
•Norfenfluramine  
去乙芬氟拉明  
•Phendimetrazine  
苯甲曲秦  
•Phentermine  
芬特明  
•Prenylamine  
普尼拉明  
•Prolintane  
普罗林坦



A stimulant not expressly listed in this section is a *Specified Substance*.  
本节未明确列出的刺激剂均为特定物质。

## **S6.B: SPECIFIED STIMULANTS**

### **特定刺激剂:**

- 2-phenylpropan-1-amine ( $\beta$ -methylphenylethyl-amine, BMPEA)  
2-苯基-1-丙胺 ( $\beta$ -甲基苯乙胺, BMPEA)
- 3-Methylhexan-2-amine (1,2-dimethylpentylamine)  
3-甲基己烷-2-胺 (1, 2-二甲基戊胺)
- 4-Fluoromethylphenidate  
4-氟哌醋甲酯
- 4-Methylhexan-2-amine (1,3-dimethylamylamine,1,3 DMAA, methylhexaneamine)  
4-甲基己烷-2-胺 (1, 3-二甲基戊胺, 1, 3 DMAA, 甲基氨基己烷)
- 4-Methylpentan-2-amine (1,3-dimethylbutylamine)  
4-甲基戊烷-2-胺 (1, 3-二甲基正丁胺)
- 5-Methylhexan-2-amine (1,4-dimethylamylamine,1,4-dimethylpentylamine, 1,4-DMAA)  
5-甲基己烷-2-胺 (1, 4-二甲基戊胺, 1, 4-DMAA)
- Benzfetamine  
苯非他明
- Cathine\*\*  
去甲伪麻黄碱\*\*
- Cathinone and its analogues, e.g. mephedrone, methedrone, and  $\alpha$ -pyrrolidinovalerophenone  
卡西酮及其同系物 (例如: 4-甲基甲卡西酮, 4-甲氧基甲卡西酮,  $\alpha$ -吡咯烷基苯戊酮)
- Dimetamfetamine(dimethylamphetamine)  
二甲基苯丙胺 (dimethylamphetamine)
- Ephedrine\*\*\*  
麻黄碱\*\*\*
- Epinephrine\*\*\*\*(adrenaline)  
肾上腺素\*\*\*\* (adrenaline)
- Etamivan  
香草二乙胺
- Ethylphenidate  
哌醋乙酯
- Etilamfetamine  
乙非他明
- Etilefrine  
依替福林
- Famprofazone  
泛普法宗
- Fenbutrazate

芬布酯  
 •Fencamfamin  
 芬坎法明  
 •Heptaminol  
 辛胺醇  
 •Hydroxyamfetamine(parahydroxyamphetamine)  
 羟苯丙胺（对-羟基苯丙胺）  
 •Isometheptene  
 异美汀  
 •Levmetamfetamine  
 左去氧麻黄碱  
 •Meclofenoxate  
 甲氯芬酯  
 •Methylenedioxymethamphetamine  
 N-甲基亚甲二氧基苯丙胺  
 •Methylephedrine\*\*\*  
 甲基麻黄碱\*\*\*  
 •Methylnaphthidate [(±)-methyl-2-(naphthalen-2-yl)-2-(piperidin-2-yl)acetate]  
 萘乙酸甲酯 [(±)-甲基-2-(萘-2-基)-2-(哌啶-2-基)乙酸酯]  
 •Methylphenidate  
 哌甲酯  
 •Midodrine  
 米多君  
 •Nikethamide  
 尼可刹米  
 •Norfenefrine  
 去甲苯福林  
 •Octodrine(1,5-dimethylhexylamine)  
 奥托君（1，5-二甲基己胺）  
 •Octopamine  
 奥克巴胺  
 •Oxilofrine(methylsynephrine)  
 奥洛福林（甲基辛弗林，又译名：甲昔奈福林）  
 •Pemoline  
 匹莫林  
 •Pentetrazol  
 戊四氮  
 •Phenethylamine and its derivatives  
 苯乙胺及其衍生物  
 •Phenmetrazine  
 芬美曲秦  
 •Phenpromethamine  
 苯丙甲胺  
 •Propylhexedrine

丙己君

•Pseudoephedrine\*\*\*\*\*

伪麻黄碱

•Selegiline

司来吉兰

•Sibutramine

西布曲明

•Solriamfetol

索安非托

•Strychnine

土的宁

•Tenamfetamine(methylenedioxyamphetamine)

替苯丙胺（亚甲二氧基苯丙胺）

Tesofensine

替索芬辛

Tuaminoheptane

异庚胺

and other substances with a similar chemical structure or similar biological effect(s).  
以及其他具有类似化学结构或类似生物效应的物质。

## EXCEPTIONS

### 例外

•Clonidine, guanfacine

可乐定，胍法辛

•Imidazoline derivatives for dermatological, nasa, ophthalmic or otic use (e.g. brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetrazyline, tramazoline, xylometazoline) and those stimulants included in the 2025 Monitoring Program\*.

皮肤、鼻腔、眼科或耳科使用的咪唑啉衍生物（例如：溴莫尼定、氯萘唑啉、非诺唑啉、茛唑啉、萘甲唑啉、羟甲唑啉、四氢唑啉、曲马唑啉、赛洛唑啉）和列入2025监控程序\*的刺激剂。

\*Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2025 Monitoring Program, and are not considered *Prohibited Substances*.

丁胺苯丙酮、咖啡因、尼古丁、去氧肾上腺素、苯丙氨醇、哌苯甲醇和昔奈福林：被列入2025监控程序，不属于禁用物质。

\*\*Cathine (d-norpseudoephedrine) and its l-isomer: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.

去甲伪麻黄碱(d-去甲伪麻黄碱)及其l-异构体：尿中浓度超过5微克/毫升时禁用。

\*\*\*Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.

麻黄碱和甲基麻黄碱：任一物质的尿中浓度超过10微克/毫升时禁用。

\*\*\*\*Epinephrine(adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents.

肾上腺素(adrenaline): 局部使用(如鼻、眼)或与局部麻醉剂合用时不禁用。

\*\*\*\*\*Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

伪麻黄碱: 尿中浓度超过150微克/毫升时禁用。

## S7. NARCOTICS

### 麻醉剂

#### PROHIBITED IN-COMPETITION

##### 赛内禁用

All prohibited substances in this class are *Specified Substances*.

本类别中所有禁用物质均为特定物质。

*Substance of Abuse* in this section: diamorphine (heroin).

本节中的滥用物质：二醋吗啡（海洛因）。

The following narcotics, including all optical isomers, e.g. *d*- and *l*- where relevant, are prohibited:

下列麻醉剂，包括所有光学异构体，例如*d*-型和*l*-型，均禁用：

•Buprenorphine

丁丙诺啡

•Dextromoramide

右吗拉胺

•Diamorphine(heroin)

二醋吗啡（海洛因）

•Fentanyl and its derivatives

芬太尼及其衍生物

•Hydromorphone

氢吗啡酮

•Methadone

美沙酮

•Morphine

吗啡

•Nicomorphine

尼可吗啡

•Oxycodone

羟考酮

•Oxymorphone

羟吗啡酮

•Pentazocine

喷他佐辛

•Pethidine

哌替啶

•Tramadol

曲马多

## S8. CANNABINOIDS

### 大麻（酚）类

#### PROHIBITED IN-COMPETITION

##### 赛内禁用

All prohibited substances in this class are *Specified Substances*.

本类别中所有禁用物质均为特定物质。

*Substance of Abuse* in this section: tetrahydrocannabinol (THC)

本节中的滥用物质：四氢大麻酚（THC）。

All natural and synthetic cannabinoids are prohibited, e.g.

所有天然和合成的大麻酚（素）类均禁用，例如：

- In cannabis (hashish, marijuana) and cannabis products;  
大麻成分（大麻脂，大麻）和大麻制品
- Natural and synthetic tetrahydrocannabinols (THCs);  
天然和合成的四氢大麻酚（THCs）
- Synthetic cannabinoids that mimic the effects of THC;  
模拟四氢大麻酚效果的合成大麻酚（素）类

#### EXCEPTIONS

##### 例外

- Cannabidiol;  
大麻二醇

## S9. GLUCOCORTICOIDS

### 糖皮质激素

#### PROHIBITED IN-COMPETITION

##### 赛内禁用

All prohibited substances in this class are *Specified Substances*.

本类别中所有禁用物质均为特定物质。

All glucocorticoids are prohibited when administered by any injectable, oral [including oromucosal (e.g. buccal, gingival, sublingual)] or rectal route.

所有糖皮质激素禁止通过任何注射、口服[包括口腔粘膜（例如：口颊、牙龈、舌下）给药]或直肠给药。

Including, but not limited to:

包括但不限于：

•Beclometasone

倍氯米松

•Betamethasone

倍他米松

•Budesonide

布地奈德

•Ciclesonide

环索奈德

•Cortisone

可的松

•Deflazacort

地夫可特

•Dexamethasone

地塞米松

•Flunisolide

氟尼缩松

•Fluocortolone

氟可龙

•Fluticasone

氟替卡松

•Hydrocortisone

氢化可的松

•Methylprednisolone

甲泼尼龙

•Mometasone

莫米松

•Prednisolone

泼尼松龙

•Prednisone

泼尼松

•Triamcinolone acetonide

曲安奈德

#### NOTE

注意

Other routes of administration (including inhaled, and topical: dental-intracanal, dermal, intranasal, ophthalmological, otic and perianal) are not prohibited when used within the manufacturer's licensed doses and therapeutic indications.

其他给药途径（包括吸入使用和外用：牙科-根管内、皮肤、鼻内、眼科、耳科和肛周）在药品说明书剂量和治疗适应症范围内不禁用。



# P1. BETA-BLOCKERS

## β-阻断剂

### PROHIBITED IN PARTICULAR SPORTS

#### 特殊运动项目禁用

All prohibited substances in this class are *Specified Substances*.

本类别所有禁用物质均为特定物质。

Beta-blockers are prohibited *In-Competition* only, in the following sports, and also prohibited *Out-of-Competition* where indicated (\*).

β-阻断剂仅在下列运动项目的赛内禁用。在标注星号（\*）的运动项目的赛外也禁用。

- Archery (WA)\*  
射箭（WA，国际射箭联合会）\*
- Automobile (FIA)  
汽车运动（FIA，国际汽车运动联合会）
- Billiards (all disciplines) (WCBS)  
台球（所有分项）（WCBS，世界台球联盟）
- Darts (WDF)  
飞镖（WDF，世界飞镖联合会）
- Golf (IGF)  
高尔夫（IGF，国际高尔夫联合会）
- Mini-Golf (WMF)  
迷你高尔夫（WMF，世界迷你高尔夫联合会）
- Shooting (ISSF, IPC) \*  
射击（ISSF，国际射击联合会，IPC，国际残奥委会）\*
- Underwater sports (CMAS) \* in all subdisciplines of freediving, spearfishing and target shooting  
水下运动（CMAS，世界水下运动联合会）\*包括自由潜水、水下渔猎和目标射击的所有分项（中文版译注：水下运动各项目暂无通用译名，均为暂译名）。

\*Also prohibited *Out-of-Competition*

\*赛外也禁用

Including, but not limited to:

包括但不限于：

- Acebutolol  
醋丁洛尔
- Alprenolol  
阿普洛尔
- Atenolol  
阿替洛尔

- Betaxolol  
倍他洛尔
- Bisoprolol  
比索洛尔
- Bunolol  
布诺洛尔
- Carteolol  
卡替洛尔
- Carvedilol  
卡维地洛
- Celiprolol  
塞利洛尔
- Esmolol  
艾司洛尔
- Labetalol  
拉贝洛尔
- Metipranolol  
美替洛尔
- Metoprolol  
美托洛尔
- Nadolol  
纳多洛尔
- Nebivolol  
奈必洛尔
- Oxprenolol;  
氧烯洛尔
- Pindolol;  
吲哚洛尔
- Propranolol;  
普萘洛尔
- Sotalol;  
索他洛尔
- Timolol.  
噻吗洛尔

## **2025 Monitoring Program\*** **2025 监控程序\***

The following substances are placed on the 2025 Monitoring Program:  
以下物质列入2025年监控程序:

### **1. Anabolic Agents:**

蛋白同化制剂:

*In and Out-of-Competition:* Ecdysterone

赛内和赛外: 蜕皮甾酮

### **2. Peptides Hormones, Growth Factors, Related Substances, and Mimetics:**

肽类激素、生长因子、相关物质和模拟物类:

*In and Out-of-Competition:* Gonadotrophin-releasing hormone (GnRH) analogs in females under 18 years only.

赛内和赛外: 18周岁以下女性使用促性腺激素释放激素类似物。

### **3. Hypoxen (polyhydroxyphenylene thiosulfonate sodium):**

Hypoxen (聚二羟基苯亚基硫代磺酸钠):

*In and Out-of-Competition*

赛内和赛外

### **4. Stimulants:**

刺激剂:

*In-Competition only:* Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol and synephrine.

仅赛内: 丁胺苯丙酮、咖啡因、尼古丁、去氧肾上腺素、苯丙氨醇、哌苯甲醇和昔奈福林。

### **5. Narcotics:**

麻醉剂:

*In-Competition only:* Codeine, demorphin (and its analogs), dihydrocodeine, hydrocodone and tapentadol.

*Out-of-Competition:* Fentanyl and tramadol

仅赛内: 可待因、皮啡肽(及其类似物)、二氢可待因、氢可酮和他喷他多。

赛外: 芬太尼和曲马多

### **6. Semaglutide:**

司美格鲁肽:

*In and Out-of-Competition*

赛内和赛外

\* The World Anti-Doping Code (Article 4.5) states: "WADA, in consultation with Signatories and governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor"

*in order to detect potential patterns of misuse in sport.”*

\* 《世界反兴奋剂条例》（条款4.5）规定：“WADA应当与各签约方和各国政府协商，就那些未列入《禁用清单》但WADA希望监控的物质建立监控程序，以便发现其在体育运动中潜在的滥用模式。”

# SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES

## 2025年《禁用清单》主要修订及注释概要

### 2025 Prohibited List

#### 2025年《禁用清单》

### SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES

#### (IN- AND OUT-OF-COMPETITION)

所有场合禁用的物质和方法（赛内和赛外）

### PROHIBITED SUBSTANCES

禁用物质

### S0. Non-approved Substances

未获批准的物质

- S-107 and S48168 (ARM210) were added to S0 as examples of the class of ryanodine receptor-1-calstabin complex stabilizers. The ryanodine receptor-1-calstabin complex is a major component of calcium storage and release, serving to maintain skeletal muscle function.
- S-107和S48168（ARM210）被列入S0类，作为兰尼碱受体-1-钙稳定蛋白复合物稳定剂的示例。兰尼碱受体-1-钙稳定蛋白复合物是钙储存和释放的主要成分，用于维持骨骼肌功能。

### S3. Beta-2 Agonists

$\beta_2$  激动剂

- Based on a recent publication<sup>1</sup> on potential performance-enhancing doses of inhaled formoterol, the dosing intervals were updated to ensure that ergogenic effects are not achieved. These new 12-hourly dosing intervals are consistent with manufacturers' recommended use; the maximum delivered dose is unchanged at 54 micrograms over 24 hours.
- 根据一篇最新发表的关于吸入一定剂量的福莫特罗可能提高运动表现的文献<sup>1</sup>，本《清单》更新了给药间隔，以确保不会产生提高运动表现的效果。新的12小时给药间隔与生产商的推荐方法一致；24小时内最大给药剂量保持不变，仍维持在54微克。

<sup>1</sup> Jeppesen JS, Jessen S, Thomassen M, Backer V, Bangsbo J, Hostrup M. Inhaled beta2-agonist, formoterol, enhances intense exercise performance, and sprint ability in elite cyclists. *Scand J Med Sci Sports*. 2024; 34: e14500. doi:10.1111/sms.14500

<sup>1</sup> Jeppesen JS, Jessen S, Thomassen M, Backer V, Bangsbo J, Hostrup M. 吸入型 $\beta_2$ 激动剂福莫特罗可提高精英自行车运动员的高强度运动表现和冲刺能力. *斯堪的纳维亚医学与运动科学杂志*. 2024; 34: e14500. doi:10.1111/sms.14500

## **S4. Hormone and Metabolic Modulators**

### **激素及代谢调节剂**

- Elacestrant was added as an example of an anti-estrogen.
- 新增艾拉司群，作为抗雌激素的示例。
- Mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) was added as an example of an AMP-activated protein kinase activator.
- 新增12S rRNA-c线粒体开放阅读框 (MOTS-c)，作为腺苷酸蛋白激酶 (AMPK) 激动剂的示例。
- For clarity, S519 and S597 were added as examples of insulin-mimetics. Insulin mimetics compounds or selective insulin receptor modulators (SIRMs) mimic insulin action by binding to the insulin receptor<sup>2</sup>.
- 为明确起见，新增S519和S597，作为胰岛素模拟物类的示例。胰岛素模拟物类化合物或选择性胰岛素受体调节剂类 (SIRMs) 通过与胰岛素受体<sup>2</sup>结合来模拟胰岛素作用。

<sup>2</sup> a) Schaffer L, Brissette RE, Spetzler JC, Pillutla RC, Østergaard S, Lennick M, Brandt J, Fletcher PW, Danielsen GM, Hsiao KC, An-dersen AS, Dedova O, Ribbel U, Hoeg-Jensen T, Hansen PH, Blume AJ, Markussen J, Goldstein NI. Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4435-9. doi:10.1073/pnas.0830026100

<sup>2</sup> a) Schaffer L, Brissette RE, Spetzler JC, Pillutla RC, Østergaard S, Lennick M, Brandt J, Fletcher PW, Danielsen GM, Hsiao KC, An-dersen AS, Dedova O, Ribbel U, Hoeg-Jensen T, Hansen PH, Blume AJ, Markussen J, Goldstein NI. 由肽构建单元组装高亲和力胰岛素受体激动剂和拮抗剂. 美国国家科学院院刊. 2003年4月15日;100(8):4435-9. doi:10.1073/pnas.0830026100

b) Schaffer L (2006) Pharmaceutically active insulin receptor-modulating molecules. PCT Int Appl WO2006018450

b) Schaffer L (2006). 药物活性胰岛素受体调节分子. PCT国际申请WO2006018450

## **S5. Diuretics and Masking Agents**

### **利尿剂和掩蔽剂**

- Xipamide was added as an example of a diuretic.
- 添加希帕胺，作为利尿剂的示例。

## **PROHIBITED METHODS**

### **禁用方法**

## **M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS**

### **篡改血液和血液成分**

- Donation of blood or blood components (e.g. plasma, red blood cells, white blood cells, platelets and peripheral blood stem cells) including by apheresis is not prohibited when performed in a collection center accredited by the relevant regulatory authority of the country in which it operates.
- 在经所在国相关监管机构认可的采集中心进行的血液或血液成分 (例如血浆、红细胞、白细胞、血小板和外周血造血干细胞) 捐献，包括通过单采术采集，不予禁止。

## **M3. GENE AND CELL DOPING**

### **基因和细胞兴奋剂**

- Minor editorial change was made for clarity.
- 为明确起见，已进行细微的编辑修改。

## **SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION**

### **赛内禁用的物质和方法**

#### **PROHIBITED SUBSTANCES**

##### **禁用物质**

#### **S6. Stimulants**

##### **刺激剂**

- Hydrafinil (fluorenol) was changed from S6.B to S6.A, as this substance is more potent than modafinil and is not licensed for medical use.
- 羟基苄（苄醇）从S6.B类移至S6.A类，因为该物质比莫达非尼效力更强，并且未获准用于医疗用途。
- Midodrine and tesofensine were added as examples of specified stimulants.
- 新增米多君和替索芬辛，作为特定刺激剂的示例。
- Guanfacine was clarified as not prohibited.
- 明确胍法辛不在禁用之列。

#### **PROHIBITED IN PARTICULAR SPORTS**

##### **特殊项目禁用的物质**

#### **P1. Beta-Blockers**

##### **β-阻断剂**

- Based on information provided by International Ski and Snowboard Federation (FIS), the skiing/snowboarding disciplines of ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air were removed.
- 根据国际滑雪和单板滑雪联合会（FIS）提供的信息，已移除跳台滑雪、自由式空中技巧 / U型场地技巧和单板滑雪U型场地技巧 / 大跳台这三个滑雪/单板滑雪分项。

#### **Monitoring Program**

##### **监控程序**

- Fentanyl and tramadol were added to monitor patterns of Out-of-Competition use.
- 监控程序新增芬太尼和曲马多，以监控其在赛外使用的模式。

\*For further information on previous modifications and clarifications, please consult the *Prohibited List* Frequently Asked Questions at

<https://www.wada-ama.org/en/prohibited-list#faq-anchor>.

\*如需了解之前有关修改和澄清的更多信息，请参阅《禁用清单》常见问题：

<https://www.wada-ama.org/en/prohibited-list#faq-anchor>

信息公开选项：主动公开